Edwards idea of “lifetime” management., page-33

All valuations aside Investek let’s look at what Edwards for example has to loose here . I heard somewhere 40% of their sales are valve on valve , would the AVR valve work better and last longer inside a Steplin valve than another Steplin ? I dare say the thought of that could scare the crap out of Edwards . If Medtronic’s where to aquire AVR the royalties payed to Edwards for any patent infringments ( millions per year ) would evaporate . IMO both of these companies have a heap to loose or gain . Edwards have the most to loose while Medtronics has the most to gain . Next issue will be can the acquirer of AVR actually charge a premium over the current valves and the answer is probably yes or at least till any comparable opposition arises . IMO these early FDA l trials could be the point the games will begin and a bidding war will start between Edwards Medtronics and possibly a few more . The general conception that AVR will attract 5 to 6 times the MC might infact get thrown out the window . At the moment neither will move until we see early FDA trials as to make a offer automatically places AVRs MC at whatever they offer GLTATH